Last €76.32 EUR
Change Today +0.021 / 0.03%
Volume 355.0
As of 3:08 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-reg (NOT) Snapshot

Open
€76.30
Previous Close
€76.30
Day High
€76.35
Day Low
€76.11
52 Week High
11/18/14 - €76.76
52 Week Low
12/16/13 - €55.19
Market Cap
206.5B
Average Volume 10 Days
20.7K
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
€2.42
Dividend Yield
2.64%
Current Stock Chart for NOVARTIS AG-REG (NOT)

novartis ag-reg (NOT) Details

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines. Its Consumer Health division offers over-the-counter medicines comprising readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. The company distributes its OTC products through various channels, such as food, drug, and mass retail outlets, as well as pharmacies; and Animal Health products directly and through wholesalers of veterinary products. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

133,000 Employees
Last Reported Date: 10/28/14
Founded in 1895

novartis ag-reg (NOT) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.3.1M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: SFr.747.1K
President of Institutes for Biomedical Resear...
Total Annual Compensation: $1.9M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: $2.0M
Division Head of Animal Health and Member of ...
Total Annual Compensation: SFr.1.4M
Compensation as of Fiscal Year 2013.

novartis ag-reg (NOT) Key Developments

QIAGEN N.V. Enters into Master Collaboration Agreement with Novartis AG

QIAGEN N.V. announced it has entered into a master collaboration agreement with Novartis AG to enable the development and commercialization of companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its development pipeline. The non-exclusive agreement with Novartis creates a framework for collaborations that would include developing QIAGEN companion diagnostics to guide treatment decisions for Novartis pharmaceutical products. The scope of the collaboration can cover all QIAGEN platforms, indications or biomarkers. The collaboration with Novartis is the ninth master framework agreement reached by QIAGEN for the development of companion diagnostics, underscoring its position as the preferred partner to pharma companies. QIAGEN is pursuing more than 20 collaborative projects with Pharma and biotech companies to develop, validate and market companion diagnostics designed to guide the treatment of cancers and other diseases. Around the world, QIAGEN already markets companion diagnostics based on molecular biomarkers, and the company has a growing portfolio of novel targets in development. The companion diagnostic programs span a range of platforms for molecular testing. A number of the diagnostics are real-time PCR assays for analysis on QIAGEN's Rotor-Gene Q, a component of the QIAsymphony family of automated instruments.

William Ackman May Sell Its Stake In Zoetis

William Ackman may sell stake in Zoetis Inc. (NYSE:ZTS) to Valeant Pharmaceuticals International, Inc. (TSX:VRX), according to people familiar with the matter. A spokesman for Zoetis said that the company got a call from William Ackman regarding the investment, but declined to comment on it. Valeant isn’t alone among potential suitors for Zoetis. Novartis AG (SWX:NOVN) and Bayer AG (BUSE:BAYER) also expressed interest in the company, people familiar with the matter have said.

Novartis AG Presents at UBS European Conference 2014, Nov-12-2014 11:00 AM

Novartis AG Presents at UBS European Conference 2014, Nov-12-2014 11:00 AM. Venue: London, United Kingdom. Speakers: Joseph Jimenez, Chief Executive Officer and Member of Executive Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOT:GR €76.32 EUR +0.021

NOT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $107.21 USD +0.51
Merck & Co Inc $59.75 USD +0.41
Pfizer Inc $31.10 USD +0.63
Roche Holding AG SFr.288.00 CHF +0.90
Procter & Gamble Co/The $88.88 USD +0.08
View Industry Companies
 

Industry Analysis

NOT

Industry Average

Valuation NOT Industry Range
Price/Earnings 23.1x
Price/Sales 3.9x
Price/Book 3.2x
Price/Cash Flow 23.9x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-REG, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.